CTLA-4 blockade in mesothelioma : ineffective or reason for optimism?
Mené sur 571 patients atteints d'un mésothéliome malin non résécable, de stade avancé et ayant récidivé après un ou deux traitements systémiques, cet essai international de phase IIb évalue l'efficacité, du point de vue de la survie globale, et la toxicité du trémélimumab en traitement de seconde ou troisième ligne
Malignant pleural mesothelioma is an aggressive disease with a poor prognosis and few treatment options. The combination of pemetrexed and cisplatin is the only approved therapy for patients with unresectable disease.1 No therapies have been approved for mesothelioma that has progressed after this initial systemic therapy. The regulatory approval of antibodies blocking immune checkpoints that function as negative regulators of T-cell function—cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4), programmed death-1 (PD-1), and programmed death ligand 1 (PD-L1)—in several different cancers2 has prompted substantial interest in the clinical investigation of these agents for mesothelioma.
The Lancet Oncology , commentaire, 2016